Features | Partner Sites | Information | LinkXpress
Sign In
FOCUS DIAGNOSTICS, INC.
Bio-Rad Diabetes Division
AB Sciex

Novel Assay Developed for Evaluating Fragile X Locus Repeats

By Labmedica International staff writers
Posted on 19 Jan 2012
A novel fragile X locus repeat assay has been developed that is a simple and high-throughput method that, with clinical validation, may be suitable for screening.

The assay uses amplification of the fragile X mental retardation 1 (FMR1) trinucleotide repeat region, followed by a hybridization assay to quantify the number of repeats in the amplicons.

Scientists working in Molecular Diagnostics at PerkinElmer Health Sciences (Waltham, MA, USA) have developed the first repeat-counting assay that uses fluorescent signals rather than electrophoresis or mass spectrometry as the signaling mechanism. They also developed a simple microfluidic electrophoresis reflex test that uses the same amplicons and reduces the need for Southern blots to differentiate homozygous female normal samples from full mutations.

The assay was tested on DNA from 1,008 dried blood spot samples from pregnant women in their first trimester. Reflex testing was performed on the 2100 Bioanalyzer (Agilent Technologies; Santa Clara, CA, USA), a compact microfluidic capillary electrophoresis platform, using the Agilent Technologies DNA 7500 kit. Before electrophoresis, the polymerase chain reaction (PCR) products were first purified using the PureLink PCR kit (Invitrogen; Grand Island, NY, USA).

The hybridization assay identified 51 of those as potentially expanded alleles of equal to or greater than 45 repeats or as intermediate or higher in FMR1 repeat classification. Of these screen-positive samples, eight were confirmed by microfluidic electrophoresis as premutations consisting of equal to or greater than 55 repeats. Results for the PCR and hybridization assay are obtained in less time than an eight-hour shift, and the confirmation electrophoresis of screen-positive results takes approximately an additional two hours. All manipulations for the PCR and hybridization assay are performed in microplates and can be performed with a multichannel pipette for high throughput, with the prospect for straightforward automation.

The Luminex 200 (Austin, TX, USA) suspension array system reads the fluorescence results of the hybridization assay unattended. The ratios of fluorescent signals indicative of the repeat length are simple to calculate and embody into software, and no visual interpretations of electropherograms are needed for the approximately 95% of samples that will assay as screen assay negative in most screening settings. The authors concluded that their preliminary results suggest that the assay is a reasonable candidate for screening maternal samples for premutation yes-no status. With appropriate clinical validation, this assay will enable high-throughput, low-cost, low-investment screening. The study was published in the November 2011 issue of the Journal of Molecular Diagnostics.

Related Links:

PerkinElmer Health Sciences
Agilent Technologies
Invitrogen




DiagCor Bioscience
77 ELEKTRONIKA
PURITAN MEDICAL
comments powered by Disqus
Life Technologies

Channels

Clinical Chemistry

view channel
Image:  The Agilent 6890 GC with 5973 Mass Spectrometer and Tekmar Velocity XPT Purge & Trap (Photo courtesy of Gen Tech).

Low Levels of Prohormone Predicts Coronary Heart Disease

The adrenal sex hormone dehydroepiandrosterone (DHEA), which is present in serum mainly as the sulfate DHEA-S, is the most abundant steroid hormone in human blood and its levels decline dramatically with age.... Read more

Microbiology

view channel
Image: The causative parasite of Chagas disease Trypanosoma cruzi in a blood film (Photo courtesy of the CDC - US Centers for Disease Control and Prevention).

Undiagnosed Chagas Disease Emerging as Public Health Threat

Chagas disease or American trypanosomiasis is typically spread to people through the feces of blood-sucking triatomine bugs sometimes called kissing bugs because they feed on people's faces during the night.... Read more

Pathology

view channel
Image: The Isolation by Size of Epithelial Tumor cells (ISET) technology (Photo courtesy of Rarecells Diagnostics).

Circulating Tumor Cells Allow Early Diagnosis of Lung Cancer

Chronic obstructive pulmonary disease (COPD) is a risk factor for lung cancer and migration of circulating tumor cells (CTCs) into the blood stream is an early event that occurs during carcinogenesis.... Read more

Industry News

view channel

Oncology Companion Diagnostics Sector Grows to Over USD 1 Billion

The market for diagnostic test and pharmaceutical drug pairs for cancer treatment has grown significantly, according to the report “Companion Diagnostic Markets” from healthcare market research firm Kalorama Information (New York City, NY, USA). The global companion diagnostics (CDx) market is valued at about USD 1.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.